---
title: "Kyntra Bio, Inc. (KYNB.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/KYNB.US.md"
symbol: "KYNB.US"
name: "Kyntra Bio, Inc."
industry: "生物技術"
---

# Kyntra Bio, Inc. (KYNB.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |
| Website | [www.kyntrabio.com](https://www.kyntrabio.com) |

## Company Profile

Kyntra Bio, Inc.是一家生物制藥公司，致力于發現、開發和商業化治療嚴重未滿足醫療需求的療法。其主要產品候選藥物 Roxadustat 是一種小分子抑制劑，能夠抑制缺氧誘導因子脯氨酸羥化酶的活性，該藥物已在中國、歐洲、日本及其他國家完成了針對慢性腎病引起的貧血的第三階段臨床開發，並且正在進行與骨髓增生異常綜合症相關的貧血的第三階段臨床開發。其產品管線包括 FG-3165 和 FG-3175，這是一種用于治療實體瘤的抗 GAL-9 抗體。該公司與 Astellas Pharma Inc.簽訂了合作協議

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-24T04:30:13.000Z

**Overall: C (0.49)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 151 / 404 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 117.53% |  |
| Net Profit YoY | 277.07% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -1.91 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 32.57M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 8.30M |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 40.09% | A |
| Profit Margin | 2598.87% | A |
| Gross Margin | -6.97% | E |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 117.53% | A |
| Net Profit YoY | 277.07% | A |
| Total Assets YoY | -48.18% | E |
| Net Assets YoY | 108.67% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 3.85% | C |
| OCF YoY | 117.53% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.04 | E |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 87.24% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Kyntra Bio, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "40.09%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "2598.87%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "-6.97%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "117.53%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "277.07%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-48.18%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "108.67%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "3.85%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "117.53%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.04",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "87.24%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制藥 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制藥 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 0.15 | 1/603 | 0.17 | 0.16 | 0.15 |
| PB | -1.91 | 495/603 | - | - | - |
| PS (TTM) | 3.92 | 84/603 | 4.42 | 4.06 | 3.80 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/KYNB.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/KYNB.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/KYNB.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.